Too little in the Melanoma release to conclude anything...well, except that it would be criminal not to continue research. The raw result of the '50' cohort is spectacular. Now let's see n=40 rather than 4.
The justification for the subgroup in the press release on RECAP is inadequate. There isn't enough emphasis on the QoL benefits, which are only mentioned. In a way, this is encouraging. If you expect to get the indication put on-label "fairly soon" (I'd set that at 18 months or so), you don't encourage off-label use (lets you do a road-show introduction when the time comes) and vice, of course, versa. The stomatitis (mouth sores) signal may be a concern--these are very vulnerable people and this may be where the opportunistic infections some of us have long feared show up.